PepGen Reports Encouraging Progress in FREEDOM2-DM1 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort - the initial dose cohort - demonstrated a favorable tolerability profile and promising efficacy trends, reinforcing our confidence in PGN-EDODM1's potential at higher doses," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "Enrollment in the 10 mg/kg cohort is now complete and we remain on track to report data in the second half of this year. With funding in place through the 10 and 12.5 mg/kg cohorts, we are well positioned to continue dose escalating and deliver on the promise of this program for the DM1 community."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 1.500
Low
3.00
Averages
11.50
High
20.00
Current: 1.500
Low
3.00
Averages
11.50
High
20.00
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PepGen Reports Q1 Earnings with Mixed Phase 2 Data
- Earnings Highlights: PepGen's Q1 GAAP EPS of -$0.26 beats expectations by $0.05, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company reported $132.3 million in cash, cash equivalents, and marketable securities, suggesting a solid financial buffer to fund operations into the second half of 2027.
- Clinical Trial Updates: PepGen released topline results from the lowest dose MAD cohort in its Phase II FREEDOM2 study, showing mixed data; however, favorable safety and other key metrics may provide support for future research.
- FDA Regulatory Challenges: The company faced a stock decline due to a partial hold from the FDA on mid-stage trials for its lead asset, highlighting the potential impact of regulatory risks on its future development.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against PepGen Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Partial Clinical Hold: On March 4, 2026, the FDA placed a partial hold on PepGen's FREEDOM2-DM1 clinical trial, questioning the preclinical pharmacology and toxicology studies, resulting in an 18.57% drop in stock price to $5.50 per share the following day.
- Clinical Data Reaction: Although PepGen characterized the clinical data released on March 30, 2026, as
See More
PepGen Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of PepGen Inc. investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns over corporate governance and compliance.
- Clinical Trial Halted: On March 4, 2026, the FDA placed a partial clinical hold on PepGen's FREEDOM2-DM1 trial, questioning previously submitted pharmacology and toxicology studies, which led to an 18.57% drop in stock price to $5.50 per share the following day, reflecting investor apprehension about the company's prospects.
- Clinical Data Disappointment: Although PepGen characterized the March 30, 2026 clinical data as
See More
PepGen Faces Securities Fraud Investigation Amid FDA Clinical Hold
- FDA Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial clinical hold on its PGN-EDODM1 FREEDOM2-DM1 trial, raising concerns about previously submitted pharmacology and toxicology studies, which resulted in a stock price drop of $1.25, or 18.57%, on March 5.
- Clinical Data Release: On March 30, 2026, PepGen released clinical data from the FREEDOM2-DM1 trial, where despite the company labeling the results as 'promising', analysts noted a lack of significant improvement in handgrip strength or 10-meter walk/run tests, leading to a further stock decline of $2.46, or 58.16%, on March 31.
- Investor Investigation: Pomerantz LLP is investigating whether PepGen and its executives engaged in securities fraud or other unlawful practices, advising investors to contact them to join the class action, highlighting significant market concerns regarding corporate governance.
- Legal Background: Pomerantz LLP, a premier firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and corporate misconduct, indicating that PepGen's legal challenges could adversely affect its future market performance.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating PepGen Inc. for potential securities fraud involving its officers, which could undermine investor confidence and lead to stock price volatility.
- Partial Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial hold on its PGN-EDODM1 clinical trial, raising concerns about previously submitted pharmacology and toxicology studies, potentially impacting future R&D progress.
- Significant Stock Price Drop: Following the FDA announcement, PepGen's stock fell by $1.25, or 18.57%, to close at $5.50 on March 5, 2026, reflecting market concerns about the company's outlook.
- Lack of Meaningful Improvement: On March 30, 2026, PepGen's clinical data was criticized by analysts for not showing significant improvements in patients' handgrip strength or 10-meter walk/run tests, leading to a further stock decline of $2.46, or 58.16%, to $1.77 on March 31, 2026.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of PepGen Inc. investors regarding potential securities fraud or unlawful business practices, indicating serious concerns about corporate governance and accountability.
- Partial Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial clinical hold on its PGN-EDODM1 trial, raising questions about previously submitted pharmacology and toxicology studies, which significantly undermined investor confidence.
- Significant Stock Price Drop: Following the FDA announcement, PepGen's stock price fell by $1.25, or 18.57%, closing at $5.50 on March 5, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Lack of Meaningful Improvement: Although PepGen characterized the clinical data released on March 30, 2026, as
See More
PepGen Reports Q1 Earnings with Mixed Phase 2 Data
- Earnings Highlights: PepGen's Q1 GAAP EPS of -$0.26 beats expectations by $0.05, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company reported $132.3 million in cash, cash equivalents, and marketable securities, suggesting a solid financial buffer to fund operations into the second half of 2027.
- Clinical Trial Updates: PepGen released topline results from the lowest dose MAD cohort in its Phase II FREEDOM2 study, showing mixed data; however, favorable safety and other key metrics may provide support for future research.
- FDA Regulatory Challenges: The company faced a stock decline due to a partial hold from the FDA on mid-stage trials for its lead asset, highlighting the potential impact of regulatory risks on its future development.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against PepGen Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Partial Clinical Hold: On March 4, 2026, the FDA placed a partial hold on PepGen's FREEDOM2-DM1 clinical trial, questioning the preclinical pharmacology and toxicology studies, resulting in an 18.57% drop in stock price to $5.50 per share the following day.
- Clinical Data Reaction: Although PepGen characterized the clinical data released on March 30, 2026, as
See More
PepGen Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of PepGen Inc. investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns over corporate governance and compliance.
- Clinical Trial Halted: On March 4, 2026, the FDA placed a partial clinical hold on PepGen's FREEDOM2-DM1 trial, questioning previously submitted pharmacology and toxicology studies, which led to an 18.57% drop in stock price to $5.50 per share the following day, reflecting investor apprehension about the company's prospects.
- Clinical Data Disappointment: Although PepGen characterized the March 30, 2026 clinical data as
See More
PepGen Faces Securities Fraud Investigation Amid FDA Clinical Hold
- FDA Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial clinical hold on its PGN-EDODM1 FREEDOM2-DM1 trial, raising concerns about previously submitted pharmacology and toxicology studies, which resulted in a stock price drop of $1.25, or 18.57%, on March 5.
- Clinical Data Release: On March 30, 2026, PepGen released clinical data from the FREEDOM2-DM1 trial, where despite the company labeling the results as 'promising', analysts noted a lack of significant improvement in handgrip strength or 10-meter walk/run tests, leading to a further stock decline of $2.46, or 58.16%, on March 31.
- Investor Investigation: Pomerantz LLP is investigating whether PepGen and its executives engaged in securities fraud or other unlawful practices, advising investors to contact them to join the class action, highlighting significant market concerns regarding corporate governance.
- Legal Background: Pomerantz LLP, a premier firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and corporate misconduct, indicating that PepGen's legal challenges could adversely affect its future market performance.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating PepGen Inc. for potential securities fraud involving its officers, which could undermine investor confidence and lead to stock price volatility.
- Partial Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial hold on its PGN-EDODM1 clinical trial, raising concerns about previously submitted pharmacology and toxicology studies, potentially impacting future R&D progress.
- Significant Stock Price Drop: Following the FDA announcement, PepGen's stock fell by $1.25, or 18.57%, to close at $5.50 on March 5, 2026, reflecting market concerns about the company's outlook.
- Lack of Meaningful Improvement: On March 30, 2026, PepGen's clinical data was criticized by analysts for not showing significant improvements in patients' handgrip strength or 10-meter walk/run tests, leading to a further stock decline of $2.46, or 58.16%, to $1.77 on March 31, 2026.
See More
PepGen Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of PepGen Inc. investors regarding potential securities fraud or unlawful business practices, indicating serious concerns about corporate governance and accountability.
- Partial Clinical Hold: On March 4, 2026, PepGen announced that the FDA placed a partial clinical hold on its PGN-EDODM1 trial, raising questions about previously submitted pharmacology and toxicology studies, which significantly undermined investor confidence.
- Significant Stock Price Drop: Following the FDA announcement, PepGen's stock price fell by $1.25, or 18.57%, closing at $5.50 on March 5, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Lack of Meaningful Improvement: Although PepGen characterized the clinical data released on March 30, 2026, as
See More
